ARWR
Price
$25.69
Change
+$3.66 (+16.61%)
Updated
Sep 2, 04:59 PM (EDT)
Capitalization
3.05B
90 days until earnings call
PBYI
Price
$5.12
Change
+$0.07 (+1.39%)
Updated
Sep 2, 04:59 PM (EDT)
Capitalization
253.87M
58 days until earnings call
Interact to see
Advertisement

ARWR vs PBYI

Header iconARWR vs PBYI Comparison
Open Charts ARWR vs PBYIBanner chart's image
Arrowhead Pharmaceuticals
Price$25.69
Change+$3.66 (+16.61%)
Volume$74.08K
Capitalization3.05B
Puma Biotechnology
Price$5.12
Change+$0.07 (+1.39%)
Volume$4.75K
Capitalization253.87M
ARWR vs PBYI Comparison Chart in %
Loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PBYI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARWR vs. PBYI commentary
Sep 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a Buy and PBYI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 03, 2025
Stock price -- (ARWR: $22.03 vs. PBYI: $5.04)
Brand notoriety: ARWR: Notable vs. PBYI: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARWR: 116% vs. PBYI: 63%
Market capitalization -- ARWR: $3.05B vs. PBYI: $253.87M
ARWR [@Biotechnology] is valued at $3.05B. PBYI’s [@Biotechnology] market capitalization is $253.87M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.25B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 1 FA rating(s) are green whilePBYI’s FA Score has 1 green FA rating(s).

  • ARWR’s FA Score: 1 green, 4 red.
  • PBYI’s FA Score: 1 green, 4 red.
According to our system of comparison, PBYI is a better buy in the long-term than ARWR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 7 TA indicator(s) are bullish while PBYI’s TA Score has 4 bullish TA indicator(s).

  • ARWR’s TA Score: 7 bullish, 4 bearish.
  • PBYI’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ARWR is a better buy in the short-term than PBYI.

Price Growth

ARWR (@Biotechnology) experienced а +3.28% price change this week, while PBYI (@Biotechnology) price change was -4.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.83%. For the same industry, the average monthly price growth was +22.37%, and the average quarterly price growth was +32.94%.

Reported Earning Dates

ARWR is expected to report earnings on Dec 01, 2025.

PBYI is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+6.83% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARWR($3.05B) has a higher market cap than PBYI($254M). PBYI YTD gains are higher at: 65.246 vs. ARWR (17.181). PBYI has higher annual earnings (EBITDA): 63.3M vs. ARWR (-52.51M). ARWR has more cash in the bank: 900M vs. PBYI (96M). PBYI has less debt than ARWR: PBYI (49.2M) vs ARWR (353M). ARWR has higher revenues than PBYI: ARWR (573M) vs PBYI (238M).
ARWRPBYIARWR / PBYI
Capitalization3.05B254M1,199%
EBITDA-52.51M63.3M-83%
Gain YTD17.18165.24626%
P/E RatioN/A5.09-
Revenue573M238M241%
Total Cash900M96M938%
Total Debt353M49.2M717%
FUNDAMENTALS RATINGS
ARWR vs PBYI: Fundamental Ratings
ARWR
PBYI
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
37
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9717
PRICE GROWTH RATING
1..100
4036
P/E GROWTH RATING
1..100
297
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PBYI's Valuation (37) in the Biotechnology industry is somewhat better than the same rating for ARWR (94). This means that PBYI’s stock grew somewhat faster than ARWR’s over the last 12 months.

PBYI's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ARWR (100). This means that PBYI’s stock grew similarly to ARWR’s over the last 12 months.

PBYI's SMR Rating (17) in the Biotechnology industry is significantly better than the same rating for ARWR (97). This means that PBYI’s stock grew significantly faster than ARWR’s over the last 12 months.

PBYI's Price Growth Rating (36) in the Biotechnology industry is in the same range as ARWR (40). This means that PBYI’s stock grew similarly to ARWR’s over the last 12 months.

ARWR's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for PBYI (97). This means that ARWR’s stock grew significantly faster than PBYI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARWRPBYI
RSI
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 5 days ago
89%
Bullish Trend 5 days ago
88%
Momentum
ODDS (%)
Bullish Trend 5 days ago
77%
Bearish Trend 5 days ago
83%
MACD
ODDS (%)
Bullish Trend 5 days ago
78%
Bearish Trend 5 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 5 days ago
76%
Bearish Trend 5 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 5 days ago
75%
Bullish Trend 5 days ago
82%
Advances
ODDS (%)
Bullish Trend 6 days ago
80%
Bullish Trend 12 days ago
85%
Declines
ODDS (%)
Bearish Trend 15 days ago
83%
Bearish Trend 6 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
85%
Bearish Trend 5 days ago
90%
Aroon
ODDS (%)
Bullish Trend 5 days ago
73%
Bearish Trend 5 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PBYI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SXGCF4.270.01
+0.23%
Southern Cross Gold Consolidated Ltd.
ASAZF34.98N/A
N/A
Assa Abloy AB
FZMD0.10N/A
N/A
Fuse Medical, Inc.
CRGGF2.48N/A
N/A
China Resources Gas Group Ltd
PBCO15.45N/A
N/A
PBCO Financial Corporation

ARWR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARWR has been loosely correlated with DNLI. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ARWR jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARWR
1D Price
Change %
ARWR100%
-1.39%
DNLI - ARWR
52%
Loosely correlated
-2.43%
IMNM - ARWR
51%
Loosely correlated
-3.94%
IPSC - ARWR
49%
Loosely correlated
-1.68%
RGNX - ARWR
48%
Loosely correlated
-0.89%
CGEM - ARWR
47%
Loosely correlated
-0.92%
More

PBYI and

Correlation & Price change

A.I.dvisor indicates that over the last year, PBYI has been loosely correlated with ARWR. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if PBYI jumps, then ARWR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PBYI
1D Price
Change %
PBYI100%
+1.41%
ARWR - PBYI
35%
Loosely correlated
-1.39%
ARCT - PBYI
34%
Loosely correlated
-1.68%
DSGN - PBYI
31%
Poorly correlated
-1.95%
FATE - PBYI
31%
Poorly correlated
-3.70%
VRCA - PBYI
31%
Poorly correlated
+0.81%
More